DSM Sinochem Pharma Wins Indian Patent Infringement Case Against Sinopharm Weiqida Pharmaceutical
Published: May 23, 2017
SINGAPORE, May 22, 2017 /PRNewswire/ -- DSM Sinochem Pharmaceuticals (DSP), the global leader in production and commercialization of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced today that the High Court of Delhi has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical for patent infringement in India.
According to DSM Sinochem Pharmaceuticals' (DSP) wholly owned subsidiaries, DSM Sinochem Pharmaceuticals Netherlands B.V. and DSM Pharmaceuticals India Pvt. Ltd., the High Court of Delhi, India, has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical Co., LTD ("Weiqida") for patent infringement of Indian Patent Number 247,301. This patent, which is owned by DSP, relates to amoxicillin trihydrate having a low free water content and processes for the manufacture thereof.
The permanent injunction prevents the manufacture, use, importation, offering for sale and sale of Weiqida's amoxicillin trihydrate active pharmaceutical ingredient in India, as well as any drug product that utilizes the active pharmaceutical ingredient.
"DSP welcomes the Court's decision," said Karl Rotthier, CEO at DSP. "The lawsuit is intended to protect DSP's world class intellectual property portfolio relating to our innovative, sustainable, and environmental friendly amoxicillin technology. DSP will continue to rigorously enforce its IP assets worldwide as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins."
About DSM Sinochem Pharmaceuticals
DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.
Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.
Please visit www.dsm-sinochem.com for more information or contact
DSM Sinochem Pharmaceuticals Corporate Communications
Alice Beijersbergen, Global Director Branding & Communications
This press release may contain forward-looking statements with respect to DSM Sinochem Pharmaceuticals' (DSP) future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSP and information currently available to the company. DSP cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSP has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dsm-sinochem-pharmaceuticals-wins-indian-patent-infringement-case-against-sinopharm-weiqida-pharmaceutical-300461850.html
SOURCE DSM Sinochem Pharmaceuticals